Last reviewed · How we verify
Acalabrutinib Treatment C
Acalabrutinib Treatment C is a BTK inhibitor Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development for Chronic lymphocytic leukemia, Mantle cell lymphoma. Also known as: AT and Pariet® (raberprazole).
BTK inhibitor
BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.
At a glance
| Generic name | Acalabrutinib Treatment C |
|---|---|
| Also known as | AT and Pariet® (raberprazole) |
| Sponsor | AstraZeneca |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Acalabrutinib is a small molecule inhibitor of Bruton's tyrosine kinase (BTK), a key component in the B-cell receptor signaling pathway.
Approved indications
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
Common side effects
- Headache
- Diarrhea
- Nausea
- Fatigue
- Cough
Key clinical trials
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (PHASE2)
- Avo In R/R And Previously Untreated MCL (PHASE1, PHASE2)
- Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. (PHASE2)
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (PHASE2)
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (PHASE1, PHASE2)
- Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acalabrutinib Treatment C CI brief — competitive landscape report
- Acalabrutinib Treatment C updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Acalabrutinib Treatment C
What is Acalabrutinib Treatment C?
How does Acalabrutinib Treatment C work?
What is Acalabrutinib Treatment C used for?
Who makes Acalabrutinib Treatment C?
Is Acalabrutinib Treatment C also known as anything else?
What drug class is Acalabrutinib Treatment C in?
What development phase is Acalabrutinib Treatment C in?
What are the side effects of Acalabrutinib Treatment C?
What does Acalabrutinib Treatment C target?
Related
- Drug class: All BTK inhibitor drugs
- Target: All drugs targeting BTK
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chronic lymphocytic leukemia
- Indication: Drugs for Mantle cell lymphoma
- Also known as: AT and Pariet® (raberprazole)
- Compare: Acalabrutinib Treatment C vs similar drugs
- Pricing: Acalabrutinib Treatment C cost, discount & access